Study of ABT-869 in Subjects With Advanced Renal Cell Carcinoma Who Have Previously Received Treatment With Sunitinib
Public ClinicalTrials.gov record NCT00486538. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
An Open-Label, Phase 2 Study to Evaluate the Efficacy and Tolerability of ABT-869 in Subjects With Advanced Renal Cell Carcinoma (RCC) Who Have Previously Received Treatment With Sunitinib
Study identification
- NCT ID
- NCT00486538
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Lead sponsor
- AbbVie (prior sponsor, Abbott)
- Industry
- Enrollment
- 53 participants
Conditions and interventions
Conditions
Interventions
- ABT-869 Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- May 31, 2007
- Primary completion
- May 31, 2011
- Completion
- May 31, 2012
- Last update posted
- Jan 3, 2013
2007 – 2012
United States locations
- U.S. sites
- 12
- U.S. states
- 8
- U.S. cities
- 9
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Site Reference ID/Investigator# 7193 | Sacramento | California | 95817 | — |
| Site Reference ID/Investigator# 5243 | Washington D.C. | District of Columbia | 20010 | — |
| Site Reference ID/Investigator# 5384 | Chicago | Illinois | 60637 | — |
| Site Reference ID/Investigator# 11662 | Boston | Massachusetts | 02114 | — |
| Site Reference ID/Investigator# 11663 | Boston | Massachusetts | 02114 | — |
| Site Reference ID/Investigator# 5379 | Boston | Massachusetts | 02114 | — |
| Site Reference ID/Investigator# 5380 | Lebanon | New Hampshire | 03756-0001 | — |
| Site Reference ID/Investigator# 5249 | Philadelphia | Pennsylvania | 19111 | — |
| Site Reference ID/Investigator# 6278 | Philadelphia | Pennsylvania | 19111 | — |
| Site Reference ID/Investigator# 6269 | Pittsburgh | Pennsylvania | 15232 | — |
| Site Reference ID/Investigator# 7300 | Charleston | South Carolina | 29425 | — |
| Site Reference ID/Investigator# 6796 | Houston | Texas | 77030-4009 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 1 non-U.S. site.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00486538, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jan 3, 2013 · Synced Jul 24, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT00486538 live on ClinicalTrials.gov.